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Introduction
Ovarian cancer is responsible for more cancer deaths
than all other gynecologic malignancies. Because of
the relatively late appearance of symptoms in most
patients with ovarian cancer, the disease is usually ad-
vanced and surgically incurable at the time of diagno-
sis. Combination chemotherapy results in complete
response in 60–80% of cases [1]. Despite the success
obtained using medical treatment, chemoresistance
remains the major obstacle to effective ovarian cancer
medical treatment. The failure of chemotherapy may
be multifactorial and related to multiple mechanisms.
Since genetic changes appear to be associated directly
with the loss of chemosensitivity in ovarian cancer, we
summarize the possible genetic changes involved in
ovarian cancer, including activation of specific onco-
genes, inactivation of tumor suppressor genes, and
downregulation of metastasis suppressor genes.
Activation of Oncogenes
Oncogenes are mutated genes that cause normal cells
to grow out of control and become cancer cells. They
are mutations of normal genes called proto-oncogenes.
Although a useful function of the proto-oncogene was
not initially apparent, and it was believed to be “silent”
or not expressed until being “switched on” to cause
uncontrolled growth, its importance in cell regulation
has been identified, which can lead to cancer when dis-
turbed. The process of activation of proto-oncogenes
to oncogenes can include retroviral transduction or
retroviral integration, point mutations, insertion
mutations, gene amplification, chromosomal trans-
location and/or protein–protein interactions [2].
Oncogenes are designated by three-letter abbrevia-
tions, such as myc, ras, and mas. The origin or location of
the gene is indicated by the prefix v- for virus or c- for
cell or chromosome; additional prefixes, suffixes, and
superscripts provide further delineation. About 60
human oncogenes have been identified. Breast cancer
has been linked to the c-neu oncogene and lung cancer
to the c-L-myc gene. Oncogenes arising in members of
the ras gene family are found in 20% of all human
cancers, including those of the lung, colon, ovary and
pancreas [2].
The list of oncogenes identified to date is too lengthy
to include here, so only oncogenes involved in ovarian
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cancer that have been highly characterized are described.
A review of the expression and role of ras, amplification
of Her2/neu (erbB2) and Her4/neu (erbB4), fms, and myc
in ovarian cancer is presented.
ras
The ras gene family has been implicated in the develop-
ment of many human epithelial cancers. ras genes en-
code highly homologous and evolutionarily conserved
Ma210,000 guanosine 5’-triphosphate (GTP)-binding
proteins, which are often activated in human ovarian
cancer [3]. These proteins, which are bound to GTP in
their active form and guanosine 5’-diphosphate (GDP)
in the inactive form, function as intermediates in signal
transduction in the inner cell membrane [4]. The three
members of the ras gene family, H-ras, K-ras and N-ras,
are among the most common oncogenes associated
with human neoplasms. Mutations in different ras genes
have been found in multiple types of human cancer,
suggesting that ras plays a key role in the development
of cancer [5]. Mutations in the different ras genes also
show remarkable tissue selectivity. For example, K-ras
mutations are common in human pancreatic cancer [6]
and colon cancer [7,8], H-ras mutations have been
found in human bladder cancer [9], and mutations in
N-ras have been observed in acute myeloid leukemia
[10].
The ras proteins play key roles in cellular regulation
[11]. ras can be activated by various extracellular stimuli
such as growth factors, cytokines, cellular adhesion
signals, and also stress signals, including irradiation and
osmotic stress [6,11]. ras-involved cellular functions
are mediated by ras downstream effectors such as raf-
1 kinase, ral-GDS, and phosphatidylinositol 3’-kinase
(PI3k). In addition, mitogen-activated protein kinase
(MAPK) kinase 1 (MEKK1) has been shown to directly
interact with GTP-bound ras, and epidermal growth
factor-induced MEKK1 activation requires ras activity,
suggesting that MEKK1 may also act as a ras downstream
effector [11]. Activation of MAPK occurs in response to
various growth stimulating signals and as a result of
activating mutations in the upstream regulators, K-ras
and B-raf, which can be found in many types of human
cancer.
The reported frequency of ras mutation in human
ovarian cancer varies considerably, partly because human
ovarian cancer is very heterogeneous. Human ovarian
cancer includes several distinct histotypes (serous,
mucinous, endometrioid, clear cell), and each histotype
can be further classified as benign, borderline, or
malignant. K-ras mutations have been found in mucinous
tumors of the ovary (11–75% of cases) and, to a lesser
extent, in non-mucinous tumors (5–36% of cases) [5].
Current data indicate that each of these histologic
subtypes is associated with distinct morphologic and
molecular genetic alterations [12]. High-grade serous
and possibly endometrioid carcinomas most probably
arise from surface epithelial inclusion glands with Tp53
mutations and dysfunction of BRCA1 and/or BRCA2.
Low-grade serous carcinomas probably arise in a
stepwise fashion in an adenoma–borderline tumor–
carcinoma sequence from typical to micropapillary
borderline tumors to low-grade invasive serous carci-
noma via activation of the ras-raf signaling pathway
secondary to mutations in K-ras and B-raf. Mucinous
carcinomas arise via an adenoma–borderline tumor–
carcinoma sequence with mutations in K-ras. Low-grade
endometrioid carcinomas arise from endometriosis via
mutations in CTNNB1 (the gene encoding beta-catenin)
and PTEN (a tumor suppressor gene).
K-ras-activating mutations occur in codons 12 and
13 and seldom in codon 61, and lead to constitutive
activation of the protein by increasing GDP/GTP
exchange or decreasing GTPase activity of the protein,
thus leading to increased cell proliferation [5]. K-ras
mutation frequencies seem to be highly related to tumor
histology. In general, K-ras mutations occur more
frequently in mucinous tumors, including borderline
malignancies, than in non-mucinous tumors such as
serous carcinomas [5]. Some mucinous borderline
tumors may progress to mucinous ovarian carcinomas
based on the finding of the same K-ras mutations in
both subtypes. K-ras mutations are less common in
serous ovarian tumors (15%) than in mucinous lesions
(47%), and more common in borderline tumors (27%)
than in invasive cancers (19%). For serous ovarian
carcinomas, K-ras status suggests an alternative
tumorigenic pathway that differs from that of mucinous
ovarian carcinomas.
K-ras mutation status is not correlated with either
International Federation of Gynecology and Obstetrics
(FIGO) stage or histologic type, whereas the presence of
K-ras mutations is significantly more frequent in well-
differentiated ovarian tumors than in moderately or
poorly differentiated ones [5]. This provides support for
the development of well-differentiated ovarian tumors
and moderately or poorly differentiated ones along
different pathways [5,13,14]. In addition, 40% of in-
vestigated mucinous ovarian tissue specimens have
a mutation in K-ras codon 12, significantly higher
than the frequency of 12% in serous ovarian tissue
specimens [5].
Ovarian tumors of borderline malignancy might
represent a pathologic continuum between benign and
invasive carcinoma. This observation was made only for
the mucinous subtype, indicating that initiation and
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progression of serous carcinomas might be different.
Interestingly, K-ras status in the study of Fabjani et al
supports the view that some serous and mucinous
borderline tumors might develop along the same
pathways [5]. In that case, genes other than K-ras might
be involved in the development of different histologic
subtypes of borderline tumors arising from benign
tissues. Singer et al also detected mutations in K-ras or
its downstream mediator B-raf in 68% of low-grade
serous carcinomas and 61% of borderline serous tumors,
implicating the K-ras pathway in these tumors as well
[14,15]. A report by Pohl et al indicated that an activated
MAPK pathway is critical in the growth and survival of
serous ovarian tumors with K-ras or B-raf mutations
[16]. Hsu et al also indicated that active MAPK is more
frequently expressed in low-grade than high-grade
ovarian serous carcinoma [17]. Active MAPK serves as
a good prognostic marker in patients with high-grade
serous carcinomas.
The molecular pathogenesis of granulosa cell tumors
of the ovary (GCT) is not understood. Jamieson et al
revealed that neither overexpression nor activating
mutations of the ras or B-raf genes are associated with
the development of GCT [18]. Endometriosis is consi-
dered to be a possible precancerous disease. Pathol-
ogically, we observed malignant transformation of
endometriosis to clear cell carcinoma or endometrio-
tic carcinoma of the ovary, via the step of atypical
endometriosis. Although endometriosis shares some
features that are characteristic of malignancy, it re-
mains unclear whether endometriosis is a precursor to
malignant disease. The DNA analysis of Otsuka et al
revealed that K-ras mutations were detectable in ovarian
clear cell carcinoma (OCCA) but not in endometriosis
or atypical endometriosis [19]. Manavi et al detected
activated c-K-ras by gene point mutation and sought
c-erbB-2 gene amplification with p185 expression in
association with the c-K-ras gene product p21 in the
human endometrium [20]. The results indicated that,
while Her2/neu (c-erbB-2) plays a role in the early
development of endometrioid carcinomas, c-K-ras gene
activation by point mutation does not. It is thought that
a number of genetic alterations are involved in malignant
transformation. It is possible that K-ras mutations are
associated with malignant transformation of atypical
endometriosis into OCCA [19], although further
research is needed to define this mechanism. Amemiya
et al suggested that K-ras mutation is associated with
malignant transformation from atypical endometriosis
to ovarian endometrioid carcinoma [21].
Previous studies have focused on identifying muta-
tions in ras genes, particularly K-ras, that are common in
mucinous or low-grade serous tumors of the ovary.
However, very few studies have addressed the effects of
H-ras, either due to mutation or activated H-ras path-
way without mutation. Also unclear is which members
of the ras family (in addition to many growth factors and
cytokines) are involved in activated ras signaling in
high-grade serous carcinoma. Mutations of H-ras
in ovarian tumors do not seem to be common; in one
study, the incidence of H-ras mutations was approxi-
mately 6% [5]. Yang et al addressed this issue by using
stably expressed H-ras small interfering RNA (siRNA)
in human ovarian cancer cells [22]. They found that H-
ras expression was critically important for maintaining
proliferation and inhibiting apoptosis. In addition,
retrovirus-mediated siRNA expression against H-ras
expression is a powerful tool to dissect ras-signaling
pathways and may be used therapeutically against
ovarian cancer.
erbB-2 (Her-2/neu)
The class I receptor tyrosine kinase family includes the
epidermal growth factor, Her-2/neu (c-erbB-2), Her-3,
and Her-4 [23]. The c-erbB-2 oncogene is located on
chromosome 17q21 and encodes a 185-kDa receptor-
like glycoprotein [23]. c-erbB-2 was originally identified
as an oncogene in chemically induced rat neuroglio-
blastomas, in which a single point mutation in the
transmembrane domain of the molecule confers
oncogenic activation [24]. In contrast, in humans, the
c-erbB-2 proto-oncogene is not activated by a point
mutation but through amplification and overexpression
of the wild-type gene [25]. Amplification of the c-erbB-
2 gene is observed in 20–30% of many cancer types, and
its overexpression is correlated with a poor prognosis
for breast and ovarian cancer patients [26–30].
The poor prognosis of ovarian and breast cancer
associated with c-erbB-2 overexpression seemed to be
sufficiently explained by a c-erbB-2–mediated high rate
of tumor cell proliferation. However, recent evidence
suggests that c-erbB-2 overexpression may also be
associated with cytotoxic drug resistance because a
dose–response effect with regard to survival was observed
in patients with c-erbB-2–negative ovarian tumors but
not in patients with c-erbB-2–positive tumors [28].
The role of c-erbB-2 in chemoresistance remains
unclear because expression of a full-length c-erbB-2
cDNA into several human breast and ovarian cancer cell
lines was not sufficient to induce resistance to cisplatin
across all of the cell lines tested [31]. The association
between overexpression of erbB-2 and resistance to
chemotherapeutic agents together with the low survival
rate and a short time to relapse associated with therapy
in many erbB-2–positive cancer patients indicates that
aberrant upregulation of erbB-2 is a critical factor in
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tumorigenesis [32,33]. Hengstler et al commented that
topoisomerase II_, which correlates with c-erbB-2
expression, is likely to contribute to the resistance of
c-erbB-2–overexpressing carcinomas [27].
Riener et al found no significant influence of erbB-2
overexpression on overall and disease-free survival
independent of FIGO stage, tumor grade, and residual
tumor mass [34]. The study revealed that tumor over-
expression of erbB-2 in women with advanced ovarian
cancer is rare and provides no prognostic information in
addition to that provided by established clinicopath-
ologic parameters. This multicenter study, however, in-
dicated that c-erbB-2 overexpression is a predictive factor
for response to first-line chemotherapy in suboptimally
debulked patients.
c-fms
The gene for the receptor tyrosine kinase for the
macrophage colony-stimulating factor (M-CSF), c-fms,
was originally determined to be the oncogene product
of the McDonough strain of feline sarcoma virus, v-fms.
The structural difference between c-fms and v-fms
amounts to only five point mutations in the extracellular
domain, two mutations in the cytoplasmic domain, and
the replacement of 50 amino acids by 14 unrelated
amino acids at the C-terminal tail [35]. In normal cells,
the life span and enzymatic activity of proto-oncogene
products are tightly regulated. Through mutation and/
or deletion of the receptor tyrosine kinase, they escape
from cellular regulatory mechanisms and are activated
constitutively without ligand binding. Roussel et al
showed that a single point mutation at position 301
was solely responsible for conversion of the human
c-fms gene product into a transforming protein [36].
However, Woolford et al showed that, in addition, a
second mutation involving residue 374 and the exchange
of the C-terminal domain were required for effective
transforming potency [37].
Co-expression of M-CSF and its receptor c-fms is
often found in ovarian epithelial carcinoma, suggesting
the existence of autocrine regulation of cell growth by
M-CSF that may modulate cellular proliferation. High
levels of c-fms transcript correlate strongly with high-
grade and advanced clinical presentations prognostic
of poor outcome and also indicate the invasive nature of
ovarian cancer [38]. However, no systematic study has
yet described the effect of chemoresistance in ovarian
cancers. To block this autocrine loop, Yokoyama et al
have developed hammerhead ribozymes against c-fms
mRNA [39]. They revealed that the ribozyme against
GUC in codon 18 of c-fms mRNA is a promising tool for
blocking the autocrine loop of M-CSF in ovarian epithelial
carcinoma.
myc
c-myc, n-myc and l-myc are the three major members of
the myc proto-oncogene family. These genes encode
proteins that play distinct but overlapping roles in a
wide range of normal and aberrant cellular processes
including cell proliferation, differentiation, apoptosis
and tumorigenesis. All three myc proteins have been
shown to bind the CACGTG (E-box) motif, a function
that is critical for the transforming activity of myc pro-
teins. Either n-myc, c-myc or l-myc can cooperate with
mutant ras to neoplastically transform primary rodent
cells. However, in such in vitro assays, the transforming
activity of l-myc is only 1–10% that of c-myc [40].
The c-myc proto-oncogene belongs to a family of
immediate-early genes, including c-fos, c-jun and
egr-1, that are rapidly induced on exposure of quiescent
cells to mitogens. While c-myc is not required for cell
proliferation, as is evident from the proliferation of
c-myc null cells, the pleiotropic transcriptional effect
of c-myc suggests that it is a central integrator and
accelerator of physiologic cell growth, proliferation and
cellular metabolism [41]. c-myc is known to be controlled
at the transcriptional and post-transcriptional levels in
many systems, and data from different laboratories
have provided evidence that c-myc protein expression
can be modulated at the translational level [41]. Casalini
et al revealed that c-myc expression was dramatically
increased in a cisplatin-resistant cell line [42]. Tashiro
et al demonstrated that overexpression of the c-myc gene
was found in 37.3% of all ovarian tumor tissues, and in
63.5% of serous adenocarcinoma tissues [43]. Significant
overexpression of the c-myc gene in stage III ovarian
cancer was observed when compared with other stages.
The increased levels of c-myc protein observed in an
ovarian carcinoma cell line stably transfected to express
HER2 has suggested a role for the HER2 pathway in c-
myc expression. Galmozzi et al demonstrated that here-
gulin (HRG) stimulation in HER2-overexpressing cells
leads to c-myc protein induction through the selective
translation of its mRNA mediated by the P2-derived
leader sequence [41]. The HRG-induced c-myc increase
was not accompanied by an equivalent enhancement
in c-myc mRNA expression or c-myc protein half-life,
demonstrating that most of the increase in the level of
c-myc protein occurred by a translational mechanism.
Iba et al determined whether and how expression of
the c-myc gene is related to the response to chemotherapy
in patients with epithelial ovarian cancer [44]. Their
study included 101 consecutive patients with stage Ic to
IV epithelial ovarian cancer who underwent primary
surgery followed by platinum-based chemotherapy. Of
the patients with a measurable lesion, 60.5% responded
to chemotherapy. Responders showed a higher
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expression of c-myc than non-responders. The receiver
operating characteristic curve according to chemo-
response demonstrated that the cut-off value of c-myc
expression was 200. Patients with c-myc expression of
more than 200 had a better 5-year survival rate than
those with lower expression (69.8% vs 43.5%). Multi-
variate analysis revealed that c-myc expression was an
independent prognostic factor. This suggests that the
expression of c-myc is related to chemoresponse and
might be a useful prognostic factor in patients with
epithelial ovarian cancer. This result is different to that
of Casalini et al, who found that c-myc expression was
increased in a cisplatin-resistant cell line [42].
l-myc has been much less intensively studied than
c-myc or n-myc and no studies have reported genetic
alterations in l-myc associated with ovarian cancers. In
contrast, c-myc is amplified in a significant fraction of
ovarian cancers. The l-myc gene on chromosome 1p34 is
amplified and overexpressed in a subset of ovarian
cancers. Amplification of c-myc on chromosome 8 has
been observed in up to 40% of primary ovarian cancers.
Wu et al used oligonucleotide microarrays and found
that l-myc was more frequently overexpressed in ovarian
cancers (relative to ovarian surface epithelium) than
either c-myc or n-myc [40]. The data implicate l-myc gene
amplification and/or overexpression in human ovarian
cancer pathogenesis. The authors observed increased
l-myc gene copy number in 15% of primary ovarian can-
cers, and overexpression of l-myc transcripts even more
frequently (40%). In situ hybridization or immunohisto-
chemical studies could provide further evidence for low
l-myc expression in normal ovarian surface epithelium
and high expression in a subset of ovarian cancers. It is
interesting that l-myc overexpression and/or amplifi-
cation seems less prevalent in mucinous ovarian cancer
compared to other tumor types. However, these findings
may be, in part, because of the relatively small number
of mucinous tumors studied [40].
Inactivation of Tumor Suppressor Genes
Tumor suppressor genes are normal genes that slow
down cell division, repair DNA mistakes, and tell cells
when to die (a process known as apoptosis or
programmed cell death) [45]. When tumor suppressor
genes do not work properly, cells can grow out of
control, which can lead to cancer. A tumor suppressor
gene is like the brake pedal on a car – it normally keeps
the cell from dividing too quickly just as a brake keeps a
car from going too fast. When something goes wrong
with the gene, such as a mutation or deletion, cell
division can get out of control.
An important difference between oncogenes and
tumor suppressor genes is that oncogenes result from
the activation (turning on) of proto-oncogenes, but
tumor suppressor genes cause cancer when they are
inactivated (turned off). Another major difference is
that while the overwhelming majority of oncogenes
develop from mutations in normal genes during the life
of the individual (acquired mutations), abnormalities
in tumor suppressor genes can be inherited as well as
acquired [45].
There are three types of tumor suppressor genes:
genes that control cell division, those that repair DNA,
and cell “suicide” genes. Because tumor suppressor
genes are recessive, cells that contain one normal and
one mutated gene (i.e. are heterozygous) still behave
normally. However, there are several mechanisms that
can cause a cell to lose its normal gene and thus be
predisposed to develop into a tumor. These may result
in a loss of heterozygosity (LOH). A second group of
tumor suppressor genes is responsible for repairing
DNA damage. Every time a cell prepares to divide into
two new cells, it must duplicate its DNA. This process is
not always perfect, and copying errors sometimes occur.
Fortunately, cells have DNA repair genes, which make
proteins that proofread DNA. But if the genes responsi-
ble for the repair are faulty, then the DNA can develop
abnormalities that may lead to cancer. When DNA
repair genes fail, mutations can slip by, allowing on-
cogenes and abnormal tumor suppressor genes to be
produced. If there is too much damage to a cell’s DNA
to be fixed by the DNA repair genes, the p53 tumor
suppressor gene is responsible for destroying the cell
by a process sometimes described as “cell suicide”
(programmed cell death or apoptosis). If the p53 gene
is not working properly, cells with DNA damage that has
not been repaired continue to grow and can eventually
become cancerous [45].
Recently, however, more and more reports describe
candidate tumor suppressors that do not conform to
this standard definition, including haploinsufficient
genes requiring inactivation of only one allele and genes
inactivated not by mutation but rather by epigenetic
hypermethylation. Paige described some of these
exceptions and proposed a revised tumor suppressor
gene definition to facilitate the identification of this new
generation of tumor suppressor loci [46].
Mutations in tumor suppressor genes have been
found in many cancers. For example, abnormalities in
the p53 gene have been found in over 50% of human
cancers. Acquired mutations in the p53 gene appear to
be involved in a wide range of cancers, including lung,
colorectal and breast cancer. The p53 gene is believed to
be among the most frequently mutated genes in human
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cancer. However, acquired changes in many other tumor
suppressor genes also contribute to the development of
sporadic cancers [45,46].
Inherited abnormalities of tumor suppressor genes
have been found in several cancers that tend to run in
families. In addition to mutations in p53, several other
mutations in tumor suppressor genes can be inherited
[45,46]. Abnormalities of the BRCA genes account for
5–10% of breast cancers and ovarian cancers. There are
many other examples of inherited tumor suppressor
gene mutations, and more are being discovered each
year. About 30 tumor suppressor genes have been
identified, including p53, BRCA1, BRCA2, LOT1, MCJ,
APC and RB1.
p53
The p53 gene has been mapped to chromosome
17p13.1. In the cell, p53 protein binds DNA, which
stimulates another gene to produce p21 protein that
interacts with a cell division-stimulating protein (cdk2)
[47]. When p21 is complexed with cdk2, the cell cannot
pass through to the next stage of cell division. Mutant
p53 can no longer bind DNA in an effective way, and as
a consequence the p21 protein is not made available to
act as the stop signal for cell division. Thus, cells divide
uncontrollably and form tumors [47].
p53 tumor suppressor gene mutations are the most
common alterations in ovarian cancer. They are often
accompanied by overexpression of the mutant form of
p53 protein. LOH studies show that chromosome 17
plays a significant role in ovarian tumor development.
On the short arm (p), LOH at 17p13.1 as well as at
a more distant locus, 17p13.3, is observed in a high
percentage of these tumors. Thus, a loss of function of
p53 often involves inactivation of one allele by point
mutation and the other by chromosomal deletion
[47].
p53 is found mutated in all of the major histogenetic
groups, including cancers of the colon, stomach, breast,
ovary, lung, brain and esophagus [48]. It is estimated
that p53 mutations are the most frequent genetic events
in human cancers and account for more than 50% of all
cases. More than 90% of the point mutations are reported
to be clustered between exons 4 and 10 and are localized
within the DNA-binding domain of the p53 protein
[49].
In ovarian cancer, p53 protein overexpression is seen
in approximately 4% of borderline tumors, 10–15% of
early, and 40–50% of advanced cancers. p53 is mutated
in approximately 40–80% of epithelial ovarian cancers
[50], but not in borderline malignancy, benign tumors,
or normal surface epithelium [47,51]. Singer et al showed
that the usual type of serous carcinoma, which is a high-
grade neoplasm, has a significantly higher frequency of
mutant p53 than low-grade invasive serous carcinoma
and serous borderline tumors [52]. The prevalence of
p53 mutations among serous tumors (51%) is higher
than that in mucinous and endometrioid tumors. The
lowest prevalence of p53 mutations is in clear cell
tumors (around 10%) [53]. The distribution of p53
mutation based on FIGO stage shows that it is more
prevalent among stage III/IV tumors (49%) compared
with stage I/II tumors (31%).
Ovarian cancers overexpress a mutant p53 protein.
These mutations are diverse but occur in evolutionarily
conserved regions of the gene (exons 5–8) that encode
functionally important parts of the molecule [47,54,
55]. The amino acid changes in these critical regions
lead to structural alterations in the protein that prevent
it from suppressing tumorigenesis.
Most p53 mutations (72%) in epithelial ovarian
cancer are transitions (from purine to purine or from
pyrimidine to pyrimidine). The high frequency of
transition mutations in p53 in ovarian cancer is similar
to the mutational spectra observed in several other
types of human cancers (e.g. breast and colon cancers),
and is thought to be characteristic of mutations that
arise spontaneously during proliferation, and that occur
during the surface repair of defects associated with
ovulation. It has been suggested that spontaneously
occurring mutations in the p53 gene may be due to
random errors in DNA synthesis and repair associated
with normal cellular proliferation [47].
The most common alteration in p53 in ovarian
cancer results in its inactivation and the overexpression
of a non-functional protein in the nucleus of the cell [47,
50]. The frequency of overexpression of mutant p53 is
significantly higher in advanced stage III/IV (40–60%)
than stage I (10–20%) disease. The higher frequency of
overexpression in advanced disease may indicate that
this is a late event in ovarian carcinogenesis. Alternatively,
it is possible that loss of p53 may confer an aggressive
phenotype associated with more rapid dissemination of
the disease [47].
Many studies have suggested that the loss of
functional p53 might confer a chemoresistant pheno-
type, due to the role of p53 in chemotherapy-induced
apoptosis [56–59]. Based on a combined immunohisto-
chemical and polymerase chain reaction (PCR)-single
strand conformation polymorphism (SSCP) analysis,
two studies suggested that tumors with p53 aberra-
tions are significantly less sensitive to cisplatin-based
chemotherapy than those with functional p53 [59,60].
In one of these studies, a correlation between p53
alteration and response to chemotherapy was found
for one specific type of mutation (missense) [60].
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Furthermore, in tumorigenic tissue, p53 protein
accumulation shown by immunohistochemistry was
observed only in cases with this type of mutation. This
result agrees with that of a study in breast cancer, which
also correlated chemoresistance with specific p53
mutations [61].
Nevertheless, in another series, no relation be-
tween p53 protein alterations, analyzed by immuno-
histochemistry and PCR followed by DNA sequencing,
and response to cisplatin-based chemotherapy was
observed [62]. Similar results were found in another
immunohistochemical study in stage II and IV disease
[63]. In addition, no correlation between chemo-
sensitivity and p53 protein accumulation was found in
another group of patients analyzed using immuno-
histochemistry combined with molecular analysis
[64]. It is likely that the status of the p53 gene is one of
numerous factors that determine sensitivity to chemo-
therapy.
The major limitation to the chemotherapeutic use of
the DNA-damaging agent cisplatin is the development
of resistance in initially responsive tumors. One of the
main pathways regulating cell survival following DNA
damage is the p53 pathway. Yazlovitskaya et al
demonstrated that in the cisplatin-sensitive ovarian
carcinoma cell line A2780 and its cisplatin-resistant
derivative CP70, resistance to cisplatin correlates with
prolonged p53 protein stabilization and accumulation
[65]. Li et al’s chemoresistance studies of cisplatin,
carboplatin and paclitaxel demonstrated the expression
of drug resistance-related genes and revealed that the
expression of p53 protein was decreased in resistant
ovarian tumor cells as compared with parental cells
[66].
LA-12, (OC-6-43)-bis(acetato)(1-adamantylamine)
amminedichloroplatinum(IV), is an octahedral platinum
(IV) complex containing a bulky hydrophobic ligand,
adamantylamine. Because of the expression of p53
protein in cisplatin-resistant ovarian tumor cells, LA-12
is significantly more efficient than cisplatin and can
overcome acquired cisplatin resistance (showing a
resistance factor 2.84-fold lower than that for cisplatin)
[67]. LA-12 increased the p53 protein level and cell cycle
perturbations in the ovarian cancer cell lines studied.
Moreover, Fraser et al suggested that the X-linked
inhibitor of apoptosis protein (Xiap), Akt2, and p53
protein are important mediators of chemoresistance in
ovarian cancer cells, and that Akt2 may be an important
regulator of both Xiap and p53 protein [68]. Inhibition
of Xiap and/or Akt expression/function may be an
effective means of overcoming chemoresistance in
ovarian cancer cells expressing either endogenous or
reconstituted wild-type p53.
BRCA1 and BRCA2
Approximately 10% of invasive ovarian carcinomas are
due to genetic predisposition and are associated with
an inherited mutation in either the BRCA1 or BRCA2
gene. Hereditary ovarian cancer due to BRCA1 or BRCA2
gene mutations accounts for roughly 5–11.7% of all
cases of ovarian cancer [69]. Women carrying germline
mutations in BRCA1 or BRCA2 have a high lifetime risk
of developing breast and/or ovarian cancer. BRCA1 is
located at chromosome 17q21 and BRCA2 is located
at chromosome 13q12–13. Female carriers of BRCA1
mutations have a 16–44% lifetime risk of developing
ovarian carcinoma, and BRCA2 mutation carriers have
a 16–27% risk [70]. The ovarian cancer risk associated
with BRCA mutation carriers up to the age of 70 years
has been reported to be as high as 66% for BRCA1 and
27% for BRCA2 [71]. Evidence suggests that the BRCA
genes act as tumor suppressor genes and regulate
cellular proliferation and DNA repair by maintaining
chromosomal integrity [72–74]. In vitro and animal
model data have demonstrated that diminished BRCA
gene product is associated with chromosomal instability
and increased proliferation of epithelial breast carcinoma
cells [75,76].
Several studies have demonstrated better survival
for patients who have hereditary BRCA-associated
ovarian carcinoma compared with those who have
sporadic ovarian carcinoma [77–80]. Two of the largest
series used genetic testing for the three common BRCA1
and BRCA2 founder mutations in predominantly
Ashkenazi Jewish populations with ovarian carcinoma
to study clinical outcome prospectively in women
with BRCA mutations (BRCA heterozygotes) [77,78].
Smaller, retrospective studies did not find a survival
benefit in BRCA mutation carriers, although those
studies used variable criteria to identify cases and controls
[80–82].
The basis for this survival advantage is unknown. It
may relate to the younger average age at diagnosis or the
different profile of molecular alterations among patients
with hereditary carcinoma. Alternatively, it is possible
that patients with BRCA-associated carcinoma have a
better response to chemotherapy treatment. This
chemosensitivity may be the result of an impaired ability
of BRCA-deficient cells to repair DNA that is damaged
by cytotoxic chemotherapy [73]. Relatively sparse data
are available on the survival of women with BRCA2-
associated ovarian tumors.
While women in both the Ashkenazi and non-
Ashkenazi populations have an estimated 1.7% lifetime
risk of acquiring malignancy, the proportion of hereditary
ovarian cancer is much higher in the Ashkenazim [83].
Most of this increased proportion of hereditary ovarian
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cancer risk is accounted for by inherited mutations in
the BRCA1 and BRCA2 genes. In the Ashkenazi Jewish
population, 29–41% of ovarian cancer is believed to be
secondary to inheriting one of three founder mutations
in BRCA1 and BRCA2, while only 10% of ovarian cancer
is attributed to mutations in these genes in non-
Ashkenazim [83]. In the study of Cass et al, 71 Jewish
women with epithelial ovarian carcinoma were tested
for the three BRCA founder mutations using SSCP
analysis, heteroduplex analysis, and protein truncation
testing [70]. In vitro chemoresistance was analyzed in 32
patients. BRCA1 heterozygotes developed epithelial
ovarian carcinoma at a younger age compared with
BRCA2 heterozygotes and women who had sporadic
ovarian carcinoma. In vitro chemoresistance correctly
predicted tumor response to platinum chemotherapy in
BRCA heterozygotes (p = 0.0096), who had a better
response to platinum chemotherapy than women who
had sporadic disease, which may have contributed to
their improved prognosis [70].
LOT1
Allelic loss in the long arm of chromosome 6 is one of the
most common genetic events in many types of human
cancers, suggesting the presence of at least one tumor
suppressor gene within this region [84]. LOH in the
distal part of 6q is an early genetic event in ovarian
and breast cancers [85,86]. In addition, deletions in
this chromosome arm are the most frequent lesions
in ovarian surface epithelial tumors of borderline
malignancy [87].
Although it is increasingly evident that deletion in
chromosome 6q is associated with human cancer, the
allelic status of different genes mapped to this
chromosomal region has not yet been elucidated. In an
in vitro model of ovarian cancer, the LOT1 (lost-on-
transformation 1) gene has altered expression in
malignant cells compared with normal progenitor cells.
LOT1 (also known as PLAGL1 or ZAC1) encodes a
transcription factor with antiproliferative potential in
cancer cells [84,88]. It is a growth suppressor gene
located on chromosome 6 at band q24–25, which is a
frequent site for LOH in many solid tumors including
ovarian cancer. The mouse ortholog of this gene was
independently identified by Spengler et al and designated
Zac1 [89], which is highly homologous to the hLOT1
and rLot1 genes. A splice variant of LOT1/ZAC1 was
identified by Kas et al and named PLAGL1 based on its
homology with the PLAG1 protein encoded by the gene
PLAG1 located on chromosome 8q12 [90]. The presence
of other genes with high homology to LOT1/ZAC1/
PLAGL1 indicates that this gene is a member of a new
family of zinc-finger proteins.
Abdollahi et al showed that LOT1 gene expression
is frequently downregulated in ovarian and breast
carcinoma cells [88,91]. LOT1 is a zinc-finger nuclear
transcription factor that possesses antiproliferative
effects and is frequently silenced in ovarian breast cancer
cells. Functional analysis of LOT1 demonstrates that it
may play a significant role as a transcription factor
modulating growth suppression through mitogenic
signaling pathways [92]. LOT1 expression is primarily
mediated by epidermal growth factor (EGF) receptor
or a related pathway, and it may regulate the growth
promoting signals as a zinc-finger motif containing
nuclear transcription factor [92]. In another study,
Abdollahi et al showed that in ovarian and breast cancer
cell lines and/or tumors, the 5’-CpG island of LOT1 is
a differentially methylated region [93]. In these cell
lines, the ratio of methylated to unmethylated CpG
dinucleotides in this region ranged from 31% to 99%,
and ovarian tumors had higher cytosine methylation
than normal tissues. Furthermore, trichostatin A, a
specific inhibitor of histone deacetylase, relieves
transcriptional silencing of LOT1 mRNA in malignantly
transformed cells. It appears that, unlike DNA
methylation, histone deacetylation does not target the
promoter, but rather is indirect and may be elicited by
a mechanism upstream of the LOT1 regulatory pathway.
Expression of LOT1 is under the control of two epigenetic
modifications and, in the absence of LOH, biallelic or
maximal silencing of LOT1 requires both processes.
Cvetkovic et al revealed that LOT1 mRNA expression
is not detectable in 39% of ovarian cancers [84], which
is consistent with previous data showing altered ex-
pression of LOT1 in different human ovarian carcinoma
cell lines. In addition, they analyzed the occurrence of
LOT1 allelic deletion in different ovarian tumor genomic
DNA samples that included papillary serous (majority),
mucinous, and primary peritoneal adenocarcinomas of
low to high grade and corresponding normal lympho-
cytes. Informative samples showed about 36.4%
LOH of this gene based on allelic loss of one or more
polymorphic sites within the LOT1 genomic sequences.
Altered expression and LOH of the LOT1 locus support
the gene’s potential role, at least in part, in the
pathogenesis of ovarian cancer and, possibly, in other
types of cancer.
MCJ
The gene for methylation-controlled J (MCJ) protein is
located at 13q14.1 and has partial homology in the
DNAJ domain with a number of proteins with a similar
domain [94]. MCJ protein has the highest similarity to
a functionally undefined protein from Caenorhabditis
elegans and is expressed as a 1.2-kb transcript in several
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adult tissues, with testis showing the highest level of
expression. Expression of MCJ is either absent or reduced
in most primary ovarian tumors and ovarian carcinoma
cell lines [94], which is attributable to deletion of one
allele and methylation of the other. MCJ expression is
associated with enhanced sensitivity to paclitaxel,
topotecan and cisplatin, suggesting that MCJ loss may
play a role in de novo chemoresistance in ovarian
carcinoma. Shridhar et al demonstrated that MCJ loss is
common in human ovarian cancer, results from the
deletion of one allele and silencing of the other by
hypermethylation, and confers resistance to the three
drugs most commonly used in the treatment of ovarian
cancer (paclitaxel, topotecan, cisplatin) [94]. They
showed that stable transfectants expressing MCJ in
OV167 are more sensitive to cisplatin, paclitaxel and
topotecan than parental and vector-transfected controls,
implicating MCJ downregulation in processes leading to
decreased drug sensitivity.
Strathdee et al reported that loss of expression of MCJ
in drug-resistant ovarian cancer cell lines depends on
methylation of a CpG island within its first exon, but is
independent of methylation within the promoter region
[95]. Furthermore, cell type-specific expression of the
MCJ gene in normal cells depends on the methylation
status of the CpG island. The MCJ CpG island is
methylated and the gene is not expressed in cells of
epithelial origin, but is unmethylated and expressed in
cells of lymphocyte or fibroblast origin. Chromatin
immunoprecipitation assays determined that MCJ CpG
island methylation is associated with loss of histone
acetylation in ovarian epithelial cells compared with
unmethylated fibroblast cells. Reduced acetylation was
observed not only within the CpG island, but also within
the promoter region, suggesting that CpG island
methylation may direct alterations in chromatin structure
within the promoter region, leading to gene inactivation.
Downregulation of Metastasis Suppressor
Genes
Metastasis suppressor genes are defined by their ability
to suppress in vivo development of metastases. They are
distinguished from tumor suppressor genes in that they
suppress metastasis without affecting primary tumor
growth. In addition, in contrast to tumor suppressor
genes, metastasis suppressor genes are rarely mutated
in metastatic cancers. Instead, downregulation of
metastasis suppressor gene expression appears to occur
most frequently through an epigenetic mechanism such
as gene methylation or through post-transcriptional/
translational modifications, suggesting that it may be
possible to reactivate endogenous metastasis suppressor
gene expression therapeutically [96].
Metastasis suppressor genes suppress the formation
of spontaneous macroscopic metastases without
affecting the growth rate of the primary tumor. To date,
five genes, nm23 (NME1), KAI1, KiSS1, BrMS1, and
mitogen-activated protein kinase kinase 4 (MKK4, also
called MAP2K4), have been shown to meet the criteria
for a metastasis suppressor gene. The role of other
genes, such as CD44 and maspin/PI5, in metastasis
suppression is less well defined [97]. The potential
mechanism of action of all of these genes has been
inferred by analogy to other family members and
observations in model systems. How these genes and
their protein products function to suppress metastasis
in vivo is the subject of enthusiastic study. Decreased
expression of the suppressor gene is the key parameter
determining metastatic potential and may occur by a
variety of mechanisms, not necessarily LOH [97]. To
date, KAI1 and nm23 are the best-characterized
metastasis suppressor genes.
KAI1
The localization of metastasis suppressor activity to rat
chromosome 2 in cell fusion experiments by Ichikawa et
al prompted the search for homologous metastasis
suppressor genes for human prostate cancer [98]. The
first such gene identified was KAI1. Microcell-mediated
chromosome transfer was used to transfer human
chromosome 11 into Dunning AT6.1 and AT3.1 rat
prostate cancer cells, and the resulting microcell hybrids
were assayed for metastasis suppression in immuno-
deficient mice [99]. These studies led to the identification
of the metastasis suppressor gene KAI1, which maps
to 11p11.2–p13. The metastasis suppressor activity of
KAI1 was subsequently demonstrated by transfecting
it into AT6.1 cells and assaying the metastatic ability
of individual transfected control cell lines in severe
combined immunodeficient mice [100].
KAI1 encodes a putative membrane protein in the
tetraspanin superfamily. Tetraspanins localize to the
cell surface, where they are believed to act as organizers
of large protein complexes regulating adhesion,
migration, growth and differentiation [96]. KAI1
expression had no effect on primary tumor growth,
meeting the requirement of a metastasis suppressor
gene. KAI1 may act as a general cancer metastasis
suppressor because downregulation is seen clinically
with the progression to metastasis in cancer of the liver,
colon, esophagus, pancreas, lung, bladder (invasive
phenotype), ovaries, cervix (grade only) and breast
[101]. Many studies also found that KAI1 expression
predicts patient survival [96,101–103].
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The mechanism by which KAI1 suppresses metastasis
is not clear. Important in KAI1 suppression may be its
interactions with certain membrane proteins implicated
in metastasis progression, including E-cadherin, `1
integrins, and EGF receptor [96]. EGF receptor and `1
integrins enhance the number of spontaneous meta-
stases from cancer cells in mice.
Impairment of cell adhesion plays a vital role in
tumor progression. E- and N-cadherin, CD9, and KAI1
are all adhesion molecules that have been implicated in
the progression of several different tumor types. There is
an inverse relationship between KAI1 and CD9 expres-
sion and ovarian tumor grade, characterized by high
expression in low-grade ovarian tumors and low ex-
pression in high-grade ovarian tumors and metastases
[104]. There is also a shift in cellular localization of KAI1
and CD9 from the membrane in grade 1 tumors to the
cytoplasm in grade 3 tumors. There is a positive trend
between N-cadherin expression and ovarian tumor grade.
E-cadherin expression varies little between different
tumor grades and metastases. Houle et al showed that
progression of ovarian epithelial carcinomas is
associated with downregulation and altered cellular
localization of KAI1 and CD9 [104]. In addition, variable
KAI1 expression during follicular and luteal development
suggests that it has a physiologic function in the ovary.
Liu et al demonstrated that KAI1 may play a role in the
malignant progression of epithelial ovarian carcinoma
through downregulation of expression rather than gene
mutation [105].
nm23
Although conflicting results have been obtained in
different solid tumors, nm23 is usually classified as a
putative metastasis suppressor gene. It is located on
the long arm of chromosome 17, which is frequently
deleted in ovarian cancer, and shows altered expression
and structure in some advanced neoplasms [106]. The
relationship between nm23 and metastatic potential
may vary between different tumor types. Reduced
expression of nm23 has been associated with poor
prognosis and increased incidence of metastases in
many epithelial tumors, such as breast [107], colon
cancer [108] and melanoma [109]. Studies on various
other tumors, including of the thyroid [110] and lung
[111], failed to show an inverse correlation. Therefore,
it has been hypothesized that nm23 may play a tissue-
specific role and that different regulatory mechanisms
may act in different tumors [112]. Despite the high
frequency (76%) of nm23-H1 LOH, the complete absence
of gene mutations in the coding portions of the retained
allele clearly indicate that, in ovarian carcinomas, this
gene does not function in the same way as classic
oncosuppressor genes [106].
The role of nm23 in gynecologic tumors has not been
extensively investigated. In ovarian cancer, the expression
of nm23 is higher than in normal ovarian tissue, benign
tumors and borderline tumors. Harlozinska et al showed
that nm23 reactivity is activated in the early stages of the
disease and that the progression of ovarian carcinoma
is accompanied by overexpression of nm23 protein
[113]. Moreover, patients with ovarian cancer and
metastatic lymph node involvement have been reported
to show lower nm23 expression than lymph node-negative
cases. Likewise, the overexpression of nm23-H1 is
associated with survival advantage and a greater
likelihood of response to chemotherapy in patients with
advanced ovarian cancer [106,112,114]. Tas et al
showed that nm23 may be a favorable prognostic factor
in ovarian cancer [115].
MKK4
MKK4, a member of the stress-activated protein kinase
(SAPK) signaling cascade, has been identified recently
as a metastasis suppressor. MKK4/JNKK1/SEK1
(hereafter referred to as MKK4), which is located on
chromosome 17p11.2, is a metastasis suppressor gene
in prostate cancer. The SAPK signaling pathway
ultimately controls transcription factors such as c-jun
[116]. Thus, MKK4 plays a role in such processes as
cellular proliferation, differentiation and apoptosis. In
highly metastatic AT6.1 prostate cancer cells, ectopic
expression of MKK4 reduces overt lung metastases by
about 80% without affecting primary tumor growth
[117].
An association between decreased MKK4 expression
and increasing Gleason grade, a predictor of metastatic
potential, supports a role for MKK4 downregulation in
clinical prostate disease [118]. Although the metastatic
patterns of spread in prostate and ovarian cancer are
clinically different, Yamada et al reported that loss of
17p is a frequent event in ovarian cancers [119]. The
expression of MKK4 in normal and metastatic ovarian
tissue was examined by Yamada et al. Normal ovarian
epithelial cells showed high-intensity staining for MKK4,
whereas metastatic tissue showed a statistically
significant decrease in expression. These results support
a role for MKK4 dysregulation in the development of
clinical disease. To test the ability of MKK4 to function
as a metastasis suppressor in vivo, MKK4 was ectopically
expressed in the highly metastatic SKOV3ip.1 human
ovarian cancer cell line to determine its effect on
metastatic colonization [119]. Taken together, these
data support a role for MKK4 in the suppression of
metastatic colonization in ovarian cancer. Further study
to elucidate mechanisms of action will be required
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before appropriate therapeutic interventions can be
formulated, but a first step will be to analyze in vivo the
combined effects of MKK4 reconstitution with standard
therapies such as chemotherapy.
Conclusion
Despite improvements in chemotherapy and the
recognition that aggressive surgical cytoreduction is
beneficial in ovarian cancer, most patients diagnosed
with ovarian cancer will die as a result of metastatic
disease. While chemotherapy is the preferred treatment
modality, chemoresistance severely limits treatment
success. The molecular changes associated with
acquisition of metastatic ability in ovarian cancer are
poorly understood. Chemoresistance of ovarian cancer
may be related to multiple mechanisms, such as
activation of specific oncogenes, inactivation of tumor
suppressor genes, and downregulation of metastasis
suppressor genes. Genetic alterations appear to be
associated directly with loss of chemosensitivity in
ovarian cancer. To help unravel the intricate network of
events that lead to chemoresistance, we have tried to
summarize the possible genes involved in ovarian cancer,
which may in the future help to identify possible targets
for new drugs and therapies. Since only those genes
involved in ovarian cancer that have been highly
characterized are described in this article, further study
of other genes responsible for chemoresistance is
required.
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